Hepatocellular carcinoma in patients with chronic kidney disease

Table 2 Liver function tests of patients with hepatocellular carcinoma, stratified according to the stage of chronic kidney disease (mean ± SD)

Variable	Total (n = 440)	Stage 1 and 2 (n = 132)	Stage 3 (n = 263)	Stages 4 and 5 (n = 45)	P value
AFP (ng/mL)	6202.1 ± 83392.3	3564.6 ± 11906.0	8176.6 ± 106579.9	1866.3 ± 4866.0	0.911
AST (U/L )	84.8 ± 77.9	94.3 ± 76.1	77.4 ± 68.6	104.3 ± 126.5	0.495
ALT (U/L)	73.0 ± 90.4	79.4 ± 79.1	64.8 ± 49.2	103.0 ± 218.9	0.150
T-bilirubin (mg/dL)	1.8 ± 3.7	1.5 ± 1.6	1.8 ± 4.3	2.8 ± 4.4	0.198
ALP (U/L)	122.4 ± 92.1	124.0 ± 76.6	114.6 ± 79.7	164.5 ± 170.2	0.072
Albumin (g/dL )	3.5 ± 0.7	3.6 ± 0.6	3.5 ± 0.7	3.2 ± 0.7	0.001
Prolonged PT (s)	1.9 ± 4.3	1.4 ± 1.2	1.6 ± 2.1	5.1 ± 12.4	0.000
Platelet count (x 103/μL)	138.2 ± 90.7	163.7 ± 109.7	126.5 ± 80.1	131.4 ± 73.0	0.037

The P value represents comparison between patients with stages 4 and 5 and patients with stages 1 and 2. AFP: Alpha-fetoprotein; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; T-bilirubin: Total bilirubin; ALP: Alkaline phosphatase; PT: Prothrombin time.